Mirtazapin +pharma (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin +pharma, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapin +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for global markets with consistent quality and on‑time delivery.

Mirtazapine is an antidepressant that acts on noradrenergic and serotonergic pathways to treat mood disorders. - Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Depression with anxiety symptoms: reduces anxiety and promotes better sleep. - Depressive episodes with insomnia: helps restore sleep patterns while treating depression. - Adjunct therapy for treatment‑resistant depression: may be added when first‑line agents are insufficient. - Depressive symptoms in chronic pain: can improve mood and pain tolerance.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome when combined with other serotonergic agents - Severe allergic reactions (anaphylaxis, skin rash)

When prescribing mirtazapine, clinicians should consider several safety measures. - Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor mood changes: watch for worsening depression or emergence of suicidal thoughts. - Use cautiously in the elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper dose under medical supervision to prevent withdrawal. - Review concomitant CNS depressants: dose adjustments may be needed. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Mirtazapine interacts with several drug classes; careful review is required. Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate serotonin syndrome. - Other serotonergic antidepressants (SSRIs, SNRIs, triptans): risk of serotonin syndrome. - CNS depressants (benzodiazepines, alcohol): may enhance sedation and respiratory depression. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase mirtazapine plasma levels. Moderate Interactions (Monitor Closely): - Anticholinergic agents: additive dry mouth and constipation. - Carbamazepine: may reduce mirtazapine concentrations. - Warfarin: possible alteration of INR, monitor coagulation parameters.